References
- Stathopoulos C, Gaillard MC, Puccinelli F, Maeder P, Hadjistilianou D, Beck-Popovic M, Munier FL. Successful conservative treatment of massive choroidal relapse in 2 retinoblastoma patients monitored by ultrasound biomicroscopy and/or spectral domain optic coherence tomography. Ophthalmic Genet. 2018 Apr;39(2):242–46.
- Kaliki S, Shields CL, Rojanaporn D, Al-Dahmash S, McLaughlin JP, Shields JA, Eagle RC Jr. High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology. 2013 May;120(5):997–1003.
- Silverman RH. High-resolution ultrasound imaging of the eye - a review. Clin Exp Ophthalmol. 2009 Jan;37(1):54–67.
- Chantada GL, Dunkel IJ, De Da´Vila MT, Abramson DH. Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol. 2004;88(8):1069–73.
- Honavar SG, Singh AD, Shields CL, Meadows AT,Demirci H, Cater J, Shields JA. Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol. 2002 Jul;120(7):923–31.
- Kaliki S, Shields CL, Shah SU, Eagle RC Jr, Shields JA, Leahey A. Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. Arch Ophthalmol. 2011 Nov;129(11):1422–27.
- Uusitalo MS, Van Quill KR, Scott IU, Matthay KK, Murray TG, O'Brien JM. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high risk features on histopathologic examination. Arch Ophthalmol. 2001;119(1):41–48.